EUVIMEDEUVIMED entdecken
Crossref

ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway

Yamei Chen, Minmin Ren, Lei Zhu, Ting Sun, Xiaoyong Wang, Lingling Jiang, Linlin Zhou, Dongyun Gao iD

Hematological Oncology · 2025

DOI: 10.1002/hon.70056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Yamei Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Dongtai Hospital of Nantong University, Dongtai, China. Hauptthemen laut MEDLINE: MicroRNAs, Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B cell lymphoma (DLBCL) is a type of common and fatal non‐Hodgkin lymphoma. This study aimed to detect the specific function of lncRNA ARAP1‐AS1 in DLBCL. The in vitro experiments were performed using RT‐qPCR, western blotting, MTT, colony formation, flow cytometry analysis, FISH, RNA pulldown, and luciferase reporter assays. A xenograft mouse model was used to evaluate tumor growth in vivo. ARAP1‐AS1 expression was upregulated in DLBCL tissues and cells. ARAP1‐AS1 knockdown inhibited DLBCL cell proliferation and promoted apoptosis. ARAP1‐AS1 activated PI3K/AKT signaling by upregulating EMP1 expression via miR‐508–5p. EMP1 overexpression markedly abolished the effect of ARAP1‐AS1 knockdown on DLBCL cell proliferation and apoptosis, and PI3K inhibitor reversed the effect of ARAP1‐AS1 overexpression on DLBCL cells. ARAP1‐AS1 knockdown inhibited DLBCL tumor growth and reduced Ki‐67, EMP1, and p ‐AKT expression in xenograft mouse models. ARAP1‐AS1 knockdown exerts anti‐tumor effect on DLBCL progression through the miR‐508–5p/EMP1/PI3K/AKT axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsLymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesRNA, Long NoncodingGene Expression Regulation, NeoplasticHumansAnimalsMiceSignal TransductionDisease ProgressionCell ProliferationMaleFemaleApoptosisCell Line, TumorMice, NudeXenograft Model Antitumor Assays

Stichwörter der Autor:innen

ARAP1‐AS1DLBCLEMP1/PI3K/AKTapoptosisproliferation

Substanzen

MicroRNAsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesRNA, Long NoncodingMIRN508 microRNA, human

Autor:innen und Institutionen

  • Department of Hematology, The Dongtai Hospital of Nantong University, Dongtai, China.
  • Department of Traditional Chinese Medicine, The Dongtai Hospital of Nantong University, Dongtai, China.
  • Department of Oncology, The Dongtai Hospital of Nantong University, Dongtai, China.

ORCID-Profile: Dongyun Gao

Zitieren

APA

Chen, Y., Ren, M., Zhu, L., Sun, T., Wang, X., Jiang, L., Zhou, L., & Gao, D. (2025). ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway. Hematological Oncology. https://doi.org/10.1002/hon.70056

Vancouver

Chen Y, Ren M, Zhu L, Sun T, Wang X, Jiang L, et al. ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway. Hematological Oncology. 2025. doi:10.1002/hon.70056

BibTeX
@article{Chen2025,
  author = {Chen, Yamei and Ren, Minmin and Zhu, Lei and Sun, Ting and Wang, Xiaoyong and Jiang, Lingling and Zhou, Linlin and Gao, Dongyun},
  title = {ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70056}
}
Kostenlos starten →